Biocon announced the signing of an exclusive licensing and supply agreement with Handok, a specialty pharmaceutical company in South Korea, for the commercialization of its vertically integrated, complex drug product, Synthetic Liraglutide.Liraglutide is an injection in pre-filled pen, used in the treatment of chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity.Under the terms of this agreement Biocon will undertake the development, manufacturing and supply of the drug product, and Handok will be responsible for obtaining regulatory approval and commercialization in the South Korean market.Handok is amongst Korea`s leading companies in the management of diabetes, offering a host of solutions from diagnosis to treatment and care. The Company`s diabetic portfolio includes products such as Amaryl, Tenelia and the recently launched Barozen Fit, a real time glucose monitoring device. Powered by Capital Market - Live News

Biocon Biologics, subsidiary of Biocon announced that the U.S. Food and Drug Administration (US FDA) has approved the Company`s first-to-file application for Yesafili� (aflibercept-jbvf), an interchangeable* biosimilar aflibercept. YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor used to treat several different types of ophthalmology conditions, is a biosimilar of its reference product EYLEA� (aflibercept). YESAFILI is intended for the treatment of neovascular (wet AMD) age-related macular degeneration, visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), visual impairment due to diabetic macular oedema (DME) and visual impairment due to myopic choroidal neovascularisation (myopic CNV). It is highly similar to the reference product Eylea� (aflibercept). Data shows that YESAFILI has comparable quality, safety, and efficacy to Eylea�.The approval of YESAFILI marks Biocon Biologics` expansion into the ophthalmology therapeutic area in the United States following a steady track record of approval in Europe (September 2023) and the United Kingdom (November 2023) where it was the first biosimilar aflibercept to be approved. The Company has secured a launch date in Canada of no later than July 1, 2025, under the terms of a settlement agreement. Shreehas Tambe, CEO & Managing Director, Biocon Biologics, said: The FDA approval of YESAFILI (aflibercept) as the first interchangeable biological product to Eylea is a significant milestone for Biocon Biologics marking our entry into Ophthalmology, a new therapeutic area in the United States. YESAFILI is approved for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy. This approval builds on our successful track record of bringing the first interchangeable insulin, SEMGLEE�, the first biosimilar Trastuzumab, OGIVRI�, and the first biosimilar Pegfilgrastim, FULPHILA�, to patients in the United States.Powered by Capital Market - Live News

Net profit of Biocon declined 56.74% to Rs 135.50 crore in the quarter ended March 2024 as against Rs 313.20 crore during the previous quarter ended March 2023. Sales rose 3.79% to Rs 3917.10 crore in the quarter ended March 2024 as against Rs 3773.90 crore during the previous quarter ended March 2023.For the full year,net profit rose 120.99% to Rs 1022.50 crore in the year ended March 2024 as against Rs 462.70 crore during the previous year ended March 2023. Sales rose 32.05% to Rs 14755.70 crore in the year ended March 2024 as against Rs 11174.20 crore during the previous year ended March 2023. ParticularsQuarter EndedYear Ended�Mar. 2024Mar. 2023% Var.Mar. 2024Mar. 2023% Var. Sales3917.103773.90 4 14755.7011174.20 32 OPM %23.3125.36 -21.7820.98 - PBDT734.80863.30 -15 3105.602301.60 35 PBT327.80499.60 -34 1536.801188.50 29 NP135.50313.20 -57 1022.50462.70 121 Powered by Capital Market - Live News

Biocon announced that the Board of Directors of the Company at its meeting held on 16 May 2024, inter alia, have recommended the final dividend of Rs 0.5 per equity Share (i.e. 10%) , subject to the approval of the shareholders.Powered by Capital Market - Live News

Biocon announced the signing of a semi-exclusive distribution and supply agreement with Medix, a specialty pharmaceutical company in Mexico, for the commercialization of its vertically integrated drug product, Liraglutide (gSaxenda), used in the treatment of chronic weight management. Under the terms of this agreement, Biocon will undertake the responsibility of obtaining regulatory approval, manufacturing and supply of the drug product, and Medix will be responsible for its commercialization in the Mexican market. Powered by Capital Market - Live News